We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genus Plc | LSE:GNS | London | Ordinary Share | GB0002074580 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -50.00 | -2.86% | 1,700.00 | 1,700.00 | 1,710.00 | 1,752.00 | 1,696.00 | 1,748.00 | 92,920 | 16:35:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 689.7M | 33.3M | 0.5043 | 33.87 | 1.13B |
From Apr 2019 to Apr 2024
World leader in animal genetics to webcast financial and operational highlights at 7:01 AM BST, 1:01 AM EDT
Genus plc (LSE: GNS), a world leading animal genetics company producing superior breeding livestock through genetic improvement, today announced that it will release its preliminary financial results for the full year ended June 30, 2020, and provide a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses, on Tuesday, September 8, 2020.
Webcast Results Presentation A pre-recorded briefing by management to discuss the preliminary results for the year ended June 30, 2020 will be held via a video webcast facility and will be accessible at the following link beginning at 7:01 AM BST, 1:01 AM EDT on September 8th: https://webcasting.buchanan.uk.com/broadcast/5f28011c65023062edd7e24a.
An archived recording of the webcast will also be available on the Investors section of the Company’s website.
About Genus Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over 75 countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency and quality, and our customers use them to supply the global dairy and meat supply chains.
Genus’s competitive edge comes from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.
Headquartered in Basingstoke, United Kingdom, Genus companies operate in over 25 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005300/en/
Company Contacts: Genus plc Stephen Wilson, Chief Executive Officer Alison Henriksen, Chief Financial Officer Tel: 01256 345970 Investor Relations and Media Contacts: United Kingdom Buchanan Charles Ryland / Chris Lane / Charlotte Slater Tel: 0207 466 5000 United States LaVoieHealthScience Donna LaVoie / Sharon Choe / Paul Sagan Tel: 617-374-8800 psagan@lavoiehealthscience.com
1 Year Genus Chart |
1 Month Genus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
